BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit. Recall
BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.
FDA recall Class II
Ongoing
FDA lists this Class II recall for BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-2067-2026
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Apr 22, 2026
- FDA report date
- May 13, 2026
- Quantity in commerce
- 106 kits (3,180 test)
- Distribution
- See key details
- FDA cause
- Under Investigation by firm
What is being recalled?
BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.
Affected model & UDI checker
Search the exact identifiers published for Z-2067-2026.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| RFIT-ASY-0138 | BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit. | Check source notice | Not specified |
FDA code information
Lot #s:0883425,0878825/DI: 00815381020192
Why was this product recalled?
Contamination to in-vitro diagnostic test may result in false positives.
These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.
What actions did Biofire Diagnostics, LLC take?
On April 22, 2026, bioMerieux issued a Urgent Medical Device Recall notification to affected consignees via E-Mail. bioMerieux asked consignees to take the following actions: 1 Examine your inventory for the lots identified in this recall notification. 2 Discontinue use and discard any remaining product from this lot in your possession. 3 Please confirm the quantity of kits that have been destroyed, previously used, or returned on the attached Acknowledgement of Receipt Form. 4 If the product has been transferred to another facility, please notify the facility and appropriate personnel. 5 If you have further distributed this product, please identify any recipients and notify them at once. 6 Please complete the accompanying Acknowledgement of Receipt Form and return to bioMrieux so that bioMrieux may acknowledge your receipt of this notification.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-2067-2026
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 20, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 20, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology